Blais E, Pichon B, Mampuya A, Antoine M, Lagarde P, Kantor G, Breton-Callu C, Lefebvre C, Gerard M, Aamarcha A, Ozsahin M, Bourhis J, Maingon P, Troussier I, Pourel N
Service de radiothérapie, institut Bergonié, 229, cours de l'Argonne, 33000 Bordeaux, France.
Service de radio-oncologie, CHUV, rue du Bugnon 46, 1011 Lausanne, Suisse.
Cancer Radiother. 2017 Oct;21(6-7):584-596. doi: 10.1016/j.canrad.2017.07.046. Epub 2017 Sep 5.
Radiation-induced lung disease (RILD) is common after radiation therapy and represents cornerstone toxicities after treatment of thoracic malignancies. From a review of literature, the objective of this article was to summarize clinical and non-clinical parameters associated with the risk of RILD in the settings of normo-fractionated radiotherapy and stereotactic body radiation therapy (SBRT). For the treatment of lung cancers with a normo-fractionated treatment, the mean lung dose (MLD) should be below 15-20Gy. For a thoracic SBRT, V20Gy<10% and MLD<6Gy are recommended. One should pay attention to central tumors and respect specific dose constraints to the bronchial tree. The recent technological improvements may represent an encouraging way to decrease lung toxicities. Finally, our team developed a calculator in order to predict the risk of radiation pneumonitis.
放射性肺病(RILD)在放射治疗后很常见,是胸部恶性肿瘤治疗后的主要毒性反应。通过文献综述,本文的目的是总结在常规分割放疗和立体定向体部放疗(SBRT)情况下与RILD风险相关的临床和非临床参数。对于采用常规分割治疗肺癌,平均肺剂量(MLD)应低于15 - 20Gy。对于胸部SBRT,建议V20Gy<10%且MLD<6Gy。应注意中央型肿瘤,并遵守对支气管树的特定剂量限制。最近的技术改进可能是降低肺部毒性的一种令人鼓舞的方法。最后,我们的团队开发了一个计算器来预测放射性肺炎的风险。